Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?

Autor Tarantelli, Chiara, Lupia, Antonio, Stathis, Anastasios, Bertoni, Francesco
Vydáno v Int J Mol Sci (2020)

An Unusual Case of Plasmablastic Lymphoma Presenting as Paravertebral Mass Evaluated by (18) F-FDG PET/CT

Autor Treglia, Giorgio, Paone, Gaetano, Stathis, Anastasios, Ceriani, Luca, Giovanella, Luca
Vydáno 2013

Genetic alterations in systemic nodal and extranodal non‐cutaneous lymphomas derived from mature T cells and natural killer cells

Autor Boi, Michela, Stathis, Anastasios, Zucca, Emanuele, Inghirami, Giorgio, Bertoni, Francesco
Vydáno v Cancer Sci (2012)

Adverse Event Reporting with Immune Checkpoint Inhibitors in Older Patients: Age Subgroup Disproportionality Analysis in VigiBase

Autor Noseda, Roberta, Bonaldo, Giulia, Motola, Domenico, Stathis, Anastasios, Ceschi, Alessandro
Vydáno v Cancers (Basel) (2021)

Do oncologists prefer subspecialty radiology reports? A quality care study

Autor Rizzo, Stefania, Del Grande, Maria, Espeli, Vittoria, Stathis, Anastasios, Nicolino, Gabriele Maria, Del Grande, Filippo
Vydáno v Insights Imaging (2021)

Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-esca...

Autor Stathis, Anastasios, Flinn, Ian W., Madan, Sumit, Maddocks, Kami, Freedman, Arnold, Weitman, Steven, Zucca, Emanuele, Munteanu, Mihaela C., Lia Palomba, M.
Vydáno v Invest New Drugs (2018)

Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response

Autor Mensah, Afua Adjeiwaa, Kwee, Ivo, Gaudio, Eugenio, Rinaldi, Andrea, Ponzoni, Maurilio, Cascione, Luciano, Fossati, Gianluca, Stathis, Anastasios, Zucca, Emanuele, Caprini, Gianluca, Bertoni, Francesco
Vydáno v Oncotarget (2014)

The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents

Autor Tarantelli, Chiara, Zhang, Lu, Curti, Elisabetta, Gaudio, Eugenio, Spriano, Filippo, Priebe, Valdemar, Cascione, Luciano, Arribas, Alberto J., Zucca, Emanuele, Rossi, Davide, Stathis, Anastasios, Bertoni, Francesco
Vydáno v Haematologica (2019)

Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma

Autor Gaudio, Eugenio, Tarantelli, Chiara, Ponzoni, Maurilio, Odore, Elodie, Rezai, Keyvan, Bernasconi, Elena, Cascione, Luciano, Rinaldi, Andrea, Stathis, Anastasios, Riveiro, Eugenia, Cvitkovic, Esteban, Zucca, Emanuele, Bertoni, Francesco
Vydáno v Oncotarget (2016)

Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628

Autor Stathis, Anastasios, Zucca, Emanuele, Bekradda, Mohamed, Gomez-Roca, Carlos, Delord, Jean-Pierre, de La Motte Rouge, Thibault, Uro-Coste, Emmanuelle, de Braud, Filippo, Pelosi, Giuseppe, French, Christopher A.
Vydáno v Cancer Discov (2016)

The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax

Autor Tarantelli, Chiara, Gaudio, Eugenio, Hillmann, Petra, Spriano, Filippo, Sartori, Giulio, Aresu, Luca, Cascione, Luciano, Rageot, Denise, Kwee, Ivo, Beaufils, Florent, Zucca, Emanuele, Stathis, Anastasios, Wymann, Matthias P., Cmiljanovic, Vladimir, Fabbro, Doriano, Bertoni, Francesco
Vydáno v Cancers (Basel) (2019)

A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors

Autor Joerger, Markus, Stathis, Anastasios, Metaxas, Yannis, Hess, Dagmar, Mantiero, Mara, Mark, Michael, Volden, Matthias, Kaindl, Thomas, Engelhardt, Marc, Larger, Patrice, Lane, Heidi, Hafner, Peter, Levy, Nicole, Stuedeli, Silvia, Sessa, Cristiana, von Moos, Roger
Vydáno v Invest New Drugs (2019)

Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors

Autor Mensah, Afua Adjeiwaa, Spriano, Filippo, Sartori, Giulio, Priebe, Valdemar, Cascione, Luciano, Gaudio, Eugenio, Tarantelli, Chiara, Civanelli, Elisa, Aresu, Luca, Rinaldi, Andrea, Damia, Giovanna, Lovati, Emanuela, Zucca, Emanuele, Stathis, Anastasios, Pietra, Claudio, Bertoni, Francesco
Vydáno v Blood Adv (2021)

Pembrolizumab in relapsed or refractory Richter syndrome

Autor Armand, Philippe, Murawski, Niels, Molin, Daniel, Zain, Jasmine, Eichhorst, Barbara, Gulbas, Zafer, Hawkes, Eliza A., Pagel, John M., Phillips, Tycel, Ribrag, Vincent, Svoboda, Jakub, Stathis, Anastasios, Chatterjee, Arkendu, Orlowski, Robert, Marinello, Patricia, Christian, Beth
Vydáno v Br J Haematol (2020)

SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model

Autor Ceriani, Luca, Gritti, Giuseppe, Cascione, Luciano, Pirosa, Maria Cristina, Polino, Angela, Ruberto, Teresa, Stathis, Anastasios, Bruno, Andrea, Moccia, Alden A., Giovanella, Luca, Hayoz, Stefanie, Schär, Sämi, Dirnhofer, Stefan, Rambaldi, Alessandro, Martinelli, Giovanni, Mamot, Christoph, Zucca, Emanuele
Vydáno v Blood Adv (2020)

Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma

Autor Mensah, Afua A., Cascione, Luciano, Gaudio, Eugenio, Tarantelli, Chiara, Bomben, Riccardo, Bernasconi, Elena, Zito, Domenico, Lampis, Andrea, Hahne, Jens C., Rinaldi, Andrea, Stathis, Anastasios, Zucca, Emanuele, Kwee, Ivo, Gattei, Valter, Valeri, Nicola, Riveiro, Maria E, Bertoni, Francesco
Vydáno v Haematologica (2018)

BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance

Autor Tarantelli, Chiara, Bernasconi, Elena, Gaudio, Eugenio, Cascione, Luciano, Restelli, Valentina, Arribas, Alberto Jesus, Spriano, Filippo, Rinaldi, Andrea, Mensah, Afua Adjeiwaa, Kwee, Ivo, Ponzoni, Maurilio, Zucca, Emanuele, Carrassa, Laura, Riveiro, Maria E, Rezai, Keyvan, Stathis, Anastasios, Cvitkovic, Esteban, Bertoni, Francesco
Vydáno v ESMO Open (2018)

Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734

Autor Spriano, Filippo, Gaudio, Eugenio, Cascione, Luciano, Tarantelli, Chiara, Melle, Federica, Motta, Giovanna, Priebe, Valdemar, Rinaldi, Andrea, Golino, Gaetanina, Mensah, Afua Adjeiwaa, Aresu, Luca, Zucca, Emanuele, Pileri, Stefano, Witcher, Michael, Brown, Bill, Wahlestedt, Claes, Giles, Francis, Stathis, Anastasios, Bertoni, Francesco
Vydáno v Blood Adv (2020)

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models

Autor Hicks, Stuart W., Tarantelli, Chiara, Wilhem, Alan, Gaudio, Eugenio, Li, Min, Arribas, Alberto J., Spriano, Filippo, Bordone, Roberta, Cascione, Luciano, Lai, Katharine C., Qiu, Qifeng, Taborelli, Monica, Rossi, Davide, Stussi, Georg, Zucca, Emanuele, Stathis, Anastasios, Sloss, Callum M., Bertoni, Francesco
Vydáno v Haematologica (2019)

Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas

Autor Stathis, Anastasios, Hotte, Sebastien J., Chen, Eric X., Hirte, Holger W., Oza, Amit M., Moretto, Patricia, Webster, Sheila, Laughlin, Anne, Stayner, Lee-Anne, McGill, Shauna, Wang, Lisa, Zhang, Wen-jiang, Espinoza-Delgado, Igor, Holleran, Julianne L., Egorin, Merrill J., Siu, Lillian L.
Vydáno 2009